我要投票 新华医疗SHINVA在医疗保健行业中的票数:717
· 外 推 电 报 ·
2026-01-09 09:18:03 星期五

【新华医疗SHINVA是哪个国家的品牌?】

新华医疗SHINVA是什么牌子?「新华医疗SHINVA」是 山东新华医疗器械股份有限公司 旗下著名品牌。该品牌发源于山东省淄博市,由创始人赵董在1943年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力新华医疗SHINVA品牌出海!将品牌入驻外推网,定制新华医疗SHINVA品牌推广信息,可以显著提高新华医疗SHINVA产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

山东新华医疗器械股份有限公司,创建于1943年,上市公司,专注于医疗器械及装备/制药装备/医疗服务的高新技术企业


2002年9月,山东新华医疗器械股份有限公司在上海证券交易所上市,现为中国医疗器械行业协会会长单位。

山东新华医疗器械股份有限公司始终坚持拼搏诚信的齐鲁文化、以用户为中心的现代企业文化为企业核心价值观,用目标鼓舞士气,用发展凝聚人心,用创新提升素质,用文化打造实力,坚定不移地走健康产业之路,坚定不移地走技术创新之路,坚定不移地走资本运作之路,拥有医疗器械及装备、制药装备、医疗服务三大业务板块。

在医疗器械板块,已形成九大配置精良、技术完备的先进产品线,涵盖感染控制、放疗及影像、手术器械及骨科、手术室工程及设备、口腔设备及耗材、体外诊断试剂及仪器、生物材料及耗材、透析设备及耗材、医用环保及其他领域。

制药装备板块,由生物制药、特种输液、中药制剂、固体制剂四大工程技术中心组成,下设八个产品技术分厂和五个控股公司,集制药装备研发、制造及销售为一体。在常规制药装备生产之外,提供着“制药工艺、制药装备、制药工程”三位一体的优质服务;同时,为化学药、生物药、植物药工厂的建设提供整包服务,为客户解决一切后顾之忧。

在医疗服务领域,新华医疗持续提升着品牌竞争力和美誉度。凭借专业的投资、建设、运营及采购和服务平台,打造具有先进医疗理念、前沿科研水平、品牌经营连锁、资源有机融合的现代化医院集团。与此同时,新华医疗也在积极拓展着肾脏健康服务,利用公司专业化、集约化、连锁化的运营优势,为医院提供新技术、新管理、新模式,创建出一系列特色鲜明的肾脏病专科医院和血液透析中心,用无限的责任感和专业度,服务于广大肾病患者。未来,新华医疗,将以集团化、专业化、规范化的全新面貌,为更多患者提供完善医疗服务,成就发展健康产业之路的宏伟梦想。

公司以山东核心区域为研发、制造、营销和管理总部,同时有北京核心区域、上海核心区域。

心系健康,诚信天下。站在新的历史起点上,面对新的发展机遇,新华医疗将一如既往,与时俱进,以自信、创新和拼搏,去勇敢面对困难和挑战,为人类健康事业、为铸造中国医疗器械产业的丰碑、打造世界知名医疗器械生产企业而继续努力奋斗!


英文翻译:Shandong Xinhua medical device Co., Ltd., founded in 1943, is a listed company. In September 2002, Shandong Xinhua medical device Co., Ltd. was listed on Shanghai Stock Exchange. Now it is the chairman of China Medical Device Industry Association. Shandong Xinhua Medical Equipment Co., Ltd. always adheres to the Qilu culture of striving for integrity, the modern enterprise culture centered on users as the core values of the enterprise, encourages morale with goals, rallies people with development, improves quality with innovation, builds strength with culture, firmly takes the road of health industry, firmly takes the road of technological innovation, and firmly takes the road of capital The way of operation, with medical devices and equipment, pharmaceutical equipment, medical services three business sectors. In the medical equipment sector, nine advanced product lines with excellent configuration and complete technology have been formed, covering infection control, radiotherapy and imaging, surgical equipment and orthopedics, operating room engineering and equipment, oral equipment and consumables, in vitro diagnostic reagents and instruments, biomaterials and consumables, dialysis equipment and consumables, medical environmental protection and other fields. The pharmaceutical equipment sector is composed of four engineering technology centers, including biopharmaceutical, special infusion, traditional Chinese medicine preparation and solid preparation. It has eight product technology branches and five holding companies, integrating the R & D, manufacturing and sales of pharmaceutical equipment. In addition to the production of conventional pharmaceutical equipment, it provides the high-quality service of "pharmaceutical technology, pharmaceutical equipment, pharmaceutical engineering"; at the same time, it provides the whole package service for the construction of chemical medicine, biological medicine, plant medicine factories, and solves all the worries for customers. In the field of medical services, Xinhua medical continues to enhance its brand competitiveness and reputation. With professional investment, construction, operation, procurement and service platform, we will build a modern hospital group with advanced medical concept, cutting-edge scientific research level, brand management chain and organic integration of resources. At the same time, Xinhua medical is also actively expanding kidney health services, taking advantage of the company's professional, intensive and chain operation advantages to provide new technology, new management and new mode for the hospital, creating a series of distinctive kidney disease specialized hospitals and hemodialysis centers, serving the vast number of nephrotic patients with unlimited sense of responsibility and professionalism. In the future, Xinhua medical will take a new look of collectivization, specialization and standardization to provide more patients with perfect medical services and achieve the grand dream of developing health industry. The company takes the core area of Shandong Province as its R & D, manufacturing, marketing and management headquarters, and has the core areas of Beijing and Shanghai. Heart health, integrity world. Standing at a new historical starting point and facing new development opportunities, Xinhua medical will, as always, keep pace with the times, bravely face difficulties and challenges with self-confidence, innovation and hard work, and continue to strive for the cause of human health, the building of a monument of China's medical device industry and the building of a world-famous medical device manufacturer!

本文链接: https://www.waitui.com/brand/e029c4041.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

华纳兄弟探索公司拒绝派拉蒙,坚持与Netflix的交易

华纳兄弟探索公司敦促股东拒绝派拉蒙的敌意收购,并重申其将工作室和流媒体资产出售给Netflix的协议是更优报价,且完成路径更明确。(新浪财经)

2小时前

Grok因涉性图像面临审查

埃隆·马斯克麾下未上市企业xAI在其Grok模型被用于生成涉性图像(包括未成年人图像)后受到抨击,这引发了监管机构对该与X平台集成的工具的调查和政策质疑。(新浪财经)

2小时前

保险公司发债规模连续三年超千亿元,多重因素推动

连续三年,保险公司发行债券规模超千亿元。刚刚过去的2025年,23家保险公司发债规模合计达1042亿元。业内人士普遍认为,这背后有多重推动因素——低利率周期下,保险公司普遍面临较高的资本补充需求;利率下行,发债成本更低,险企有动力发新债置换旧债;也有险企希望在利率低位时融资以进一步夯实资本实力、增厚发展安全垫。另外,在逆周期监管思路下,保险公司发债也在一定程度上获得了监管部门的支持。(证券时报)

2小时前

中信建投:白酒板块迎来周期底部配置机会

36氪获悉,中信建投指出,白酒产业“五底阶段”(政策底、库存底、动销底、批价底、产销底)与资本市场“三低一高”(预期低、估值低、公募持仓低、高分红)共振,结合近期市场策略相继落地,站在春节旺季来临之际,认为本轮白酒调整期拐点将至,资本市场预期先行,白酒板块迎来周期底部配置机会。

2小时前

CrowdStrike以7.4亿美元收购身份安全初创公司SGNL

网络安全提供商CrowdStrike周四宣布,将以近7.4亿美元的价格收购身份管理初创公司SGNL,以在人工智能网络攻击时代加强防御。该公司表示,此次收购将帮助CrowdStrike的Falcon云安全平台用户更好地管理人员和人工智能身份访问请求以及实时风险。该交易预计将于2027财年第一季度完成。(新浪财经)

2小时前

本页详细列出关于新华医疗SHINVA的品牌信息,含品牌所属公司介绍,新华医疗SHINVA所处行业的品牌地位及优势。
咨询